Latest News

Novozymes bags Organobalance

Enzyme fermentation at Novozymes' pilot plant, in Bagsværd, Denmark © Novozymes


Denmark’s Novozymes has acquired microbial research company Organobalance GmbH. The German company owns a large collection of microbial strains, some of which date back to the 1920s, and has strong capabilities in microbial screening and assay technology.

Germany-based Organobalance specializes in developing natural microbial solutions for customers and partners across a number of industries including food, feed, and animal health. Now, the company with a staff of 29  has been bought up by Danish industrial enzymes and microorganism expert Novozymes for an undisclosed amount.

“The experience of Organobalance’s founding scientists, and the company’s know-how, immediately strengthen Novozymes’ existing capabilities within microbial technologies,” says Sebastian Søderberg, Vice President for New Business Development, Incubation & Acquisitions at Novozymes. “Organobalance will advance our understanding to develop new, sustainable solutions across industries, and provide us with additional commercial opportunities.”

Organobalance co-founder Christine Lang will continue as General Manager. Lang commented: “By becoming part of Novozymes, we will have access to a global R&D network and an extensive infrastructure to bring products to market – a clear advantage for us and our customers."

Staten Biotechnology in $430m deal with Novo Nordisk

Under the agreement, Dutch Staten Biotechnology B.V. and Novo Nordisk A/S will collaborate to co-develop Staten's preclinical dyslipidemia...

Investors pool €27m for new Proteomics tech

Developed at the University of Cambridge, Fluidic Analytics’ platform is designed to give insights into the way that proteins fold, aggregate and...

Epigenetic drugs can increase tumour malignancy

In Nature Cell Biology the team headed by Salvador Aznar Benitah and Fran Supek reported that genetic inactivation of histone H3...

Diverse cells make up the endothelium

Endothelial dysfunction has been recently highlighted as a hallmark in many severe disorders including cardiovascular diseases. However,...

Kurma Partners announce closing of Biofund III

Kurma Biofund III, which is backed by cornerstone investors Servier, Bpifrance, and Idinvest, will invest in private biopharmaceutical companies....

Afyren raises €21m to launch production plant

Together with its historical shareholders AFY Partners and Sofimac Régions Afyren has raised more than €60m to move its zero-waste fermentation...

BioFIT: innovation and investors

Around 1.500 people came to Lille to participate in the event. BioFIT is hitting a nerve, says Etienne Varvaecke. The general manager of Eurosanté,...